The Fc protein and glycoengineered antibodies market

  • Blog Title
    Blog posted on : 02-02-2022

    The Fc protein and glycoengineered antibodies market



    Roots Analysis has announced the addition of “Fc Protein and Glyco-engineered Antibodies Market, 2021-2030” report to its list of offerings.


    Over time, a substantial body of evidence has validated the therapeutic applications of Fc engineering platforms; Fc modified antibodies have shown to augment the various immune effector functions, such as antibody-dependent cellular cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), antibody-dependent cellular phagocytosis (ADCP) activity and / or the half-life of the molecule


    To order this 250+ page report, which features 100+ figures and 110+ tables, please visit


    Key Market Insights

    The Fc engineered antibodies pipeline features more than 125 marketed drugs / drug development programs

    Around 15% Fc protein and glyco-engineered antibodies are marketed, while close to 75% are being evaluated in different phases of clinical trials and 10% in preclinical studies. Examples of marketed Fc engineered antibodies include Gazvya®, Imfinzi®, MONJUVI® and Skyrizi®.  


    Around 30 companies claim to be engaged in the development of Fc protein and glyco-engineered antibodies

    Around 55% of the aforementioned players are large companies (with more than 5000 employees). It is worth highlighting that, majority of the developers engaged in this domain (54%) are based in North America, followed by Europe (26%) and Asia-Pacific (20%).

    To request a sample copy / brochure of this report, please visit this



    For additional details, please visit

    or email



    You may also be interested in the following titles:

    1. TIL-based Therapies Market, 2021-2030
    2. TCR-based Therapies Market, 2021-2030
    3. Peptide Therapeutics Market, 2021-2030




    Ben Johnson

    +1 (415) 800 3415